Ken O’Rourke leads O’Melveny’s Los Angeles Litigation Practice where he represents established and emerging companies in complex, multi-forum civil litigation in federal and state courts. In 2015, Mr. O’Rourke serves as interim Chief Legal Officer of one of the nation’s largest health insurance companies. He is admitted to practice in California and as a solicitor on the roll in England & Wales. He is the immediate past Chair of the California State Bar Antitrust & Unfair Competition Law Section Executive Committee, and is a member of the ABA Antitrust Section’s International Cartel Task Force.
178
This article has been nominated for the 2016 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. The Federal Trade Commission (“FTC”) has reached a settlement resolving its claims that Cephalon, Inc. violated the antitrust laws by entering into reverse payment (...)
396
But Decision Raises as Many Questions as it Answers The Supreme Court yesterday held that it may be unlawful under the antitrust laws for a brand-name drug manufacturer to resolve patent litigation against an allegedly infringing generic drug maker by paying the generic to forestall market (...)
1728
The authors of this Trends focus on several decisions delivered in the United States and in Europe, related to pay-for-delay settlements in the pharmaceutical sector. This type of settlements has spread in the past few years, and aim to postpone the arrival of generics on the market, with (...)
19 avenue Jean Aicard
75011 Paris, France
106 West 32nd Street, Suite 144
New York, NY, 10001, USA
563 Chiswick High Road
W4 3AY London, UK
